Customize
Quick Links
Past Events

Accreditation/
Credit Designation

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Physicians’ Education Resource®, LLC and Pharmacy Times Continuing Education. Physicians’ Education Resource®, LLC is accredited by the ACCME to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC designates this live activity for a maximum of 22.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians' Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669 for 22.0 Contact Hours.


Pharmacy Times Continuing Education is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for a maximum of 22.0 contact hours (0.22 CEUs).

Acknowledgment of Commercial Support

This activity is supported by educational grants from Ariad Pharmaceuticals, Inc., Astellas, AstraZeneca, Celgene Corporation, Clovis Oncology, Eisai, Exelixis, Inc., Genomic Health, Inc., Incyte, Lilly, Medivation, Inc., Merck, NantHealth, Inc., Novartis Pharmaceuticals Corporation, Novocure Inc., Pfizer, Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Sirtex, Taiho Oncology, Inc., Takeda Oncology, Tesaro, Inc., and Teva Pharmaceuticals.

For further information concerning Lilly grant funding visit www.lillygrantoffice.com.



The CFS™ Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® is wholly owned and operated by PER Events, LLC, an affiliate of Physicians' Education Resource®.
About
Accreditation
Privacy Policy
Terms & Conditions
Executive Board
Journal
Faculty Portal
Contact
Facebook
Twitter
LinkedIn
Google +
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 1-609-378-3701

Copyright © 2018
Physicians’ Education Resource ®, LLC.
All rights reserved.

34th Annual CFS™ Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®

34th Annual CFS™ Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®


PER Pulse™ Recap

Resources

34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow ® Online: Clinical Vignette Series
Earn up to 2.0 AMA PRA Category 1 Credits™
34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Online: Clinical Vignette Series is an online continuing medical education (CME)‒certified activity.

PER Pulse™ Recap
PER Pulse™ Recaps for the 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Online: Clinical Vignette Series


PER Pulse™ Recap

PER Pulse™ Recap



1 of 3
PER Pulse Recap

34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Online: Clinical Vignette Series is a series of short video interviews with faculty from the Symposium who address a variety of questions commonly faced by practicing community oncologists via discussion of clinical vignettes that were presented. The activity features case-based discussions on:

  • Frontline therapy for stage IV lung adenocarcinoma by Ben Levy, MD
  • EGFR-mutation‒positive non-small cell lung cancer by Ben Levy, MD
  • Frontline therapy for stage IV, BRAF-mutated melanoma by Jason Luke, MD
  • Second-line therapy for metastatic renal cell carcinoma by Robert Figlin, MD
  • Residual disease after neoadjuvant therapy for breast cancer by Debu Tripathy, MD
  • Immunotherapy in triple-negative breast cancer by Debu Tripathy, MD

Throughout the activity, these physicians answer questions about their decisions for case management, and offer perspective and guidance on issues important to community-based physicians.

This first of 3 PER Pulse™ Recaps summarizing the program focuses on Dr. Levy’s answers to questions about frontline treatment for stage IV lung cancer. During his interview, Dr. Levy:

  • Discusses his approach for a 71-year-old female with a 45-pack-year smoking history who presented with cough and fatigue, and was found to have stage IV lung adenocarcinoma (right upper lobe mass, bilateral pulmonary nodules) with no genetic aberrations in EGFR, ALK, or ROS1.
  • Shares his perspective on a variety of issues, including when to order molecular testing and criteria for immunotherapy selection in the frontline versus second-line setting (histology, PD-L1 expression).
  • Talks about efforts to optimize upfront therapies for patients with stage IV lung cancer, and early data regarding combination therapy with PD-1 and CTLA4 inhibitors.


2 of 3
PER Pulse™ Recap

34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Online: Clinical Vignette Series is a series of short video interviews with faculty from the Symposium who address a variety of questions commonly faced by practicing community oncologists via discussion of clinical vignettes that were presented. The activity features case-based discussions on:

  • Frontline therapy for stage IV lung adenocarcinoma by Ben Levy, MD
  • EGFR-mutation‒positive non-small cell lung cancer by Ben Levy, MD
  • Frontline therapy for stage IV, BRAF-mutated melanoma by Jason Luke, MD
  • Second-line therapy for metastatic renal cell carcinoma by Robert Figlin, MD
  • Residual disease after neoadjuvant therapy for breast cancer by Debu Tripathy, MD
  • Immunotherapy in triple-negative breast cancer by Debu Tripathy, MD

Throughout the activity, these physicians answer questions about their decisions for case management, and offer perspective and guidance on issues important to community-based physicians.

This second of 3 PER Pulse™ Recaps summarizing the program focuses on Dr. Luke’s answers to questions about frontline therapy for stage IV melanoma. During his interview, Dr. Luke:

  • Discusses his approach for a 53-year-old male with good performance status (PS) and elevated lactase dehydrogenase (LDH) who has been diagnosed with stage IV, BRAF-mutated melanoma involving the liver, lymph nodes, and bone.
  • Talks about the challenge of selecting therapy for patients with melanoma. For a patient with rapidly progressing disease, Dr. Luke would consider a targeted therapy prior to immunotherapy. Approximately one-third of patients who receive targeted therapy have positive long-term outcomes; however, retrospective data indicate that these benefits are limited primarily to patients with low LDH. The combination of a PD-1 inhibitor and a CTLA-4 inhibitor appears to provide long-term benefit to patients with high-risk disease (eg, multiple sites of disease, declining PS, high LDH).
  • Shares his approach toward treatment planning with immunotherapies. In the second-line metastatic setting, sequential administration of a PD-1 inhibitor followed by a CTLA-4 inhibitor seems to provide clinical benefit versus the reverse sequence. For a patient who may not do well enough to get both treatments sequentially, Dr. Luke would consider giving PD-1 and CTLA-4 inhibitors concurrently.
  • Reviews the latest data regarding sequencing of immunotherapies and tyrosine kinase inhibitors, dosing, biomarkers, and adverse events. Dr. Luke is excited to see the outcomes of several trials looking at combination therapy with a BRAF inhibitor plus an anti-PD-1 antibody, pembrolizumab plus an IDO inhibitor, and T-VEC (attenuated oncolytic virus talimogene laherparepvec) plus pembrolizumab.

3 of 3
PER Pulse™ Recap

34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Online: Clinical Vignette Series is a series of short video interviews with faculty from the Symposium who address a variety of questions commonly faced by practicing community oncologists via discussion of clinical vignettes that were presented. The activity features case-based discussions on:

  • Frontline therapy for stage IV lung adenocarcinoma by Ben Levy, MD
  • EGFR-mutation‒positive non-small cell lung cancer by Ben Levy, MD
  • Frontline therapy for stage IV, BRAF-mutated melanoma by Jason Luke, MD
  • Second-line therapy for metastatic renal cell carcinoma (RCC) by Robert Figlin, MD
  • Residual disease after neoadjuvant therapy for breast cancer by Debu Tripathy, MD
  • Immunotherapy in triple-negative breast cancer by Debu Tripathy, MD

Throughout the activity, these physicians answer questions about their decisions for case management, and offer perspective and guidance on issues important to community-based physicians.

This third of 3 PER Pulse™ Recaps summarizing the program focuses on Dr. Figlin’s answers to questions about therapy for advanced RCC. During his interview, Dr. Figlin:

  • Discusses his approach for a 50-year-old female diagnosed with metastatic, clear-cell RCC who progressed after 9 months of therapy with sunitinib 50 mg per day on the 4-weeks-on and 2-weeks-off schedule.
  • Reviews standards of care in the second-line metastatic setting and his approach toward therapeutic selection, including specific scenarios that drive his decisions.
  • Shares his thoughts on overall survival and subgroup analysis data from trials of cabozantinib and nivolumab presented or published within the past year.
  • Discusses the potential impact of longer follow-up and independent radiologic review of data from the phase II CABOSUN trial of cabozantinib versus sunitinib in the first-line, metastatic RCC setting.
  • Comments on future clinical trial data that will shape practice, including the PROTECT trial of adjuvant pazopanib for patients with high-risk RCC and the ADAPT trial of autologous dendritic cell immunotherapy plus sunitinib for patients with advanced RCC.







Become a Member

Forgot Password?
Calendar of Events
SUNMONTUESWEDTHURSFRISAT
     12
3456789
10111213141516
17181920212223
24252627282930
Filter By